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OBJECTIVE — To determine how glucose control in women with GDM treated with met-
formin and/or insulin inﬂuenced pregnancy outcomes.
RESEARCH DESIGN AND METHODS — Women randomly assigned to metformin or
insulin treatment in the Metformin in Gestational Diabetes (MiG) trial had baseline glucose
tolerance test (OGTT) results and A1C documented, together with all capillary glucose mea-
surements during treatment. In the 724 women who had glucose data for analysis, tertiles of
baseline glucose values and A1C and of mean capillary glucose values during treatment were
calculated.Therelationshipsbetweenmaternalfactors,glucosevalues,andoutcomes(including
a composite of neonatal complications, preeclampsia, and large-for-gestational-age [LGA] and
small-for-gestational-age infants) were examined with bivariable and multivariate models.
RESULTS — Baseline OGTT did not predict outcomes, but A1C predicted LGA infants (P 
0.003). During treatment, fasting capillary glucose predicted neonatal complications (P 
0.001) and postprandial glucose predicted preeclampsia (P  0.016) and LGA infants (P 
0.001). Obesity did not inﬂuence outcomes, and there was no interaction between glycemic
control, randomized treatment, or maternal BMI in predicting outcomes. The lowest risk of
complications was seen when fasting capillary glucose was 4.9 mmol/l (mean  SD 4.6  0.3
mmol/l) compared with 4.9–5.3 mmol/l or higher and when 2-h postprandial glucose was
5.9–6.4 mmol/l (6.2  0.2 mmol/l) or lower.
CONCLUSIONS — Glucose control in women with gestational diabetes mellitus treated
withmetforminand/orinsulinisstronglyrelatedtooutcomes.Obesityisnotrelatedtooutcomes
in this group. Targets for fasting and postprandial capillary glucose may need to be lower than
currently recommended.
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A
lthough treatment of gestational di-
abetes mellitus (GDM) has been
shown to improve perinatal out-
comes (1,2), there is lack of consensus
about ideal glucose targets and how other
factors, such as fetal abdominal circum-
ference, should inﬂuence these targets
(3,4). The Fifth International Workshop-
Conference on Gestational Diabetes en-
dorsed targets of capillary fasting glucose
5.3 mmol/l, 1-h postprandial 7.8
mmol/l, and/or 2-h postprandial 6.7
mmol/l until further data addressing op-
timal goals become available (5). Im-
proved pregnancy outcomes have been
reported in women achieving these tar-
gets compared with those in women who
did not (6); the latter group had higher
baseline mean BMI and A1C, which may
have inﬂuenced outcomes. Obesity has
been reported as an independent factor
inﬂuencing outcome in women with
GDM treated with diet but not in those
treated with insulin (7,8).
Published studies have compared
women who aim for or achieve predeter-
mined glucose targets with those who do
not: it is not clear whether such aims are
optimal and whether glycemia inﬂuences
different outcomes equally. Several stud-
ies suggested that treatment intensity can
beusefullystratiﬁedaccordingtofetalab-
dominal circumference measured by ul-
trasound (3): intensive treatment of
women carrying fetuses with an abdomi-
nal circumference above the 70–75th
percentileloweredthefrequencyoflarge-
for-gestational-age (LGA) infants without
increasing rates of small-for-gestational-
age (SGA) infants. However, lowering of
mean maternal glucose to 4.8 mmol/l is
associated with increased frequency of
SGA infants (9).
Data showing relationships between
different fasting and postprandial glucose
values and a range of outcomes would as-
sist clinicians in setting target ranges for
“optimal glucose control” more objec-
tively.IntheMetformininGestationalDi-
abetes (MiG) trial, women with GDM,
who had one or more home capillary
blood glucose measures 5.5 mmol/l
fasting or 6.7 mmol/l 2-h postprandial
afterlifestyleintervention,wererandomly
assigned to either insulin or metformin
treatment (10). The primary objective of
the trial was to compare metformin with
insulin treatment, but prespeciﬁed sec-
ondary objectives were to determine the
impact of glycemia on outcomes and to
determine whether treatment with met-
formin or insulin was more effective at
different levels of glycemia. Baseline gly-
cemia measures and capillary glucose
measures throughout treatment were re-
corded in the trial database. The speciﬁc
aims of the present analysis were 1)t o
determine how glucose control inﬂu-
enced trial outcomes, including the pri-
mary outcome (a composite of neonatal
complications), maternal preeclampsia,
and rates of LGA and SGA infants; 2)t o
identify additional baseline factors inﬂu-
encing outcomes, including baseline gly-
cemia and obesity; and 3) to examine any
differencesbetweentreatmentarmsatdif-
ferent levels of glycemia.
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METHODS— The MiG trial was a
prospective, randomized, multicenter
trial comparing metformin with insulin
treatment in women with GDM. The
methodology and outcomes have been
publishedpreviously(10).Themeanges-
tation at recruitment was 30  3 weeks.
All women gave written informed con-
sent. The trial was approved by ethics
committees at each participating site.
Assessment of glycemia
Baseline glycemia measures included the
diagnostic75-goralglucosetolerancetest
(OGTT) results and A1C at random as-
signment to treatment with insulin or
metformin.Treatmentglycemiameasures
included capillary glucose measurements
that were documented four times daily:
fastingand2hfromthestartofeachmeal.
Medisense (now Optium) meters (Abbott
Diabetes Care, Alameda, CA) and occa-
sional Accu-Chek Advantage meters
(Roche Diagnostics, Mannheim, Ger-
many) were used, and the stored results
were downloaded. Relevant results were
transcribed into the trial database from
the day after medication was started until
delivery. Of 733 women who had data
collected, 7 women did not have fasting
glucose, 8 did not have postprandial glu-
cose, and 9 did not have any glucose re-
cordings documented, leaving 724
womenforassessment.Themediannum-
ber (interquartile range) of capillary glu-
cose values documented for each woman
included 46 (34–60) fasting and 115
(83–161) postprandial measures. The
meansoffastingandpostprandialglucose
measures were calculated separately for
each patient.
Outcomes and deﬁnitions
Several prespeciﬁed outcomes from the
trial were selected to examine the impact
of glycemia measures: the primary out-
come composite (neonatal complica-
tions), preeclampsia, and rates of LGA
(customized birth weight 90th percen-
tile) and SGA (customized birth weight
10th percentile) infants. The primary
outcomecompositeincludedoneormore
of the following neonatal complications:
recurrent hypoglycemia (two or more
blood glucose measurements 2.6
mmol/l), respiratory distress (need for
4 h of respiratory support with supple-
mental oxygen, continuous positive air-
way pressure, or intermittent positive-
pressure ventilation during ﬁrst 24 h),
need for phototherapy, birth trauma,
5-min Apgar score 7, and preterm birth
(37 weeks of gestation). The birth
weight percentile was calculated using cus-
tomized calculators (http://www.gestation.
net), which adjust for sex and gestational
age of the infant as well as for maternal
height, weight in early pregnancy, ethnic
group, and parity (11). In this calculator,
birth weight is adjusted if a woman’s BMI
is between 20 and 30 kg/m
2 but not fur-
ther adjusted for BMI above this range;
European, Maori, Chinese, Indian, and
otherspeciﬁcAsianandPaciﬁcIslandeth-
nicities can be selected. In the MiG data-
base, the speciﬁc Paciﬁc Island ethnicity
was not documented, so Samoan ethnic-
itywasusedtorepresentthisgroupinthe
calculations. Of note, customized charts
applied to a general nondiabetic obstetric
population with ethnicities similar to
those of the MiG population report rates
of SGA infants between 12.1 and 12.8%
andofLGAinfantsbetween8.4and8.8%
(http://www.adhb.govt.nz/nwhealthinfo).
Statistical analysis
Mean capillary glucose values were calcu-
lated from the daily records. They are
shown as mean fasting, mean postpran-
dial, and/or overall mean glucose (mean
fastingplusmeanpostprandialdividedby
2). Fasting, postprandial, and overall
mean glucose measures and their rela-
tionshiptooutcomeswereexploredusing
continuous measures and categorized
quartileandtertilegroupings;allmethods
yielded similar relationships. Tertile
groups were chosen for this report be-
cause,withlargernumbersineachgroup,
they provided a simple demonstration of
relationships between glucose levels and
outcomes. A bivariable analysis of base-
line characteristics was performed to ex-
plore associations with outcomes.
Interactions with glycemic control, both
of randomized treatment (metformin or
insulin) and of obesity, were explored us-
ing the Breslow-Day test through strati-
ﬁed analysis and logistic regression
analysis. Multivariable binary logistic re-
gression was performed to identify inde-
pendent risk factors associated with both
the primary composite outcome measure
and preeclampsia. For the customized
birth weight percentiles, multinomial lo-
gistic regression was used, given that the
outcome measure was categorized into
threegroups:appropriate-for-gestational-
age, SGA, and LGA infants. In these anal-
yses, the backwards elimination method
was used. Speciﬁcally, any potential risk
factors identiﬁed through bivariable anal-
ysis and stratiﬁed analysis (P  0.25), as
well as others considered potentially rel-
evant for clinical reasons or from the lit-
erature, were included in the initial
models; variables were then eliminated
stepwise from the models if their contri-
butions were not signiﬁcant, until all
variables retained were signiﬁcantly asso-
ciated with the outcome measure. Two
multivariableanalysismodelswereexam-
ined. In the ﬁrst, the glycemic measures
included the baseline OGTT results, A1C
values, and mean fasting, postprandial,
and overall capillary glucose concentra-
tions in addition to other potential base-
line risk factors (total available n  582
for this model for the primary composite
outcome). In the second model, the base-
line glycemia measures were excluded,
giving a total n  724 for the analysis of
primary composite measures. Interpreta-
tion of the results relating to risk factors
for SGA and LGA infants took into ac-
count the fact that the “customized” clas-
siﬁcation of SGA and LGA infants had
already been adjusted for infant sex, ges-
tation, maternal ethnicity, parity, and
BMI between 20 and 30 kg/m
2.
Maternal weight at the earliest book-
ing was missing in 147 women, so these
data were imputed using a regression
method. Speciﬁcally, the weight was ﬁrst
imputed using a formula based on the
postpregnancyweight.Ifthisvariablewas
missing, then a formula based on the ran-
domization weight was used instead. The
imputed mean of weight at the earliest
booking was 85.98 kg, very close to the
mean of 85.25 kg before imputation, sug-
gesting that the imputation is robust.
All analyses were performed using
SAS (version 9.1; SAS Institute, Cary,
NC), using 0.05 to determine
signiﬁcance.
RESULTS— Table 1 shows tertiles of
baseline glycemia measures and capillary
glucose levels during treatment. Supple-
mentary Table 1A (available at http://care.
diabetesjournals.org/cgi/content/full/dc09-
1407/DC1)showsbaselinecharacteristics
of the women according to tertiles of cap-
illary glucose during treatment.
The relationships between tertiles of
mean fasting, postprandial, and overall
capillary glucose during treatment and
outcomes are shown in Table 2. Examin-
ing the components of the primary out-
come composite, we note that the
frequencies of recurrent neonatal hypo-
glycemia and preterm birth increased
across tertiles of control, and there was a
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tress and a need for phototherapy. Mater-
nal preeclampsia and frequency of LGA
infants also increased across tertiles of
achieved glycemia. The frequency of SGA
infantsfellacrossthetertilesoffastingand
mean glycemia but not across the post-
prandial tertiles. The frequency of SGA
infantsinthelowestfastingtertilewasnot
increasedcomparedwiththatoftheback-
ground population.
The bivariable relationships between
maternal baseline characteristics, glyce-
mia measures, and outcomes are shown
in Table 3. Baseline factors that were re-
lated to the primary outcome composite
included maternal ethnicity, nulliparity,
previous preeclampsia, and previous de-
livery of a baby weighing 4,000 g. Base-
line glycemia measures were not related
to the primary outcome composite, but
meancapillaryglucosemeasuresontreat-
ment were strongly related. Preeclampsia
was associated with Polynesian ethnicity,
chronichypertension,previoushyperten-
sivecomplicationsduringpregnancy,and
maternal weight gain from early preg-
nancy to recruitment. It was also associ-
ated with baseline A1C and all measures
of glucose control on treatment. Addi-
tional factors (not all shown) that were
not related to either the primary outcome
composite or preeclampsia included ges-
tation at recruitment (20–27 vs. 28–33
weeks), tertiary education level, smoking
in pregnancy, past history of GDM, pre-
vious recurrent miscarriage/termination
(threeormore),andmaternalﬁrst-degree
family history of diabetes, hypertension,
or preeclampsia.
In Table 3, the frequency of SGA in-
fants was associated with Asian ethnicity
and with the woman having a ﬁrst-degree
relative with diabetes. It was inversely re-
lated to maternal weight gain from early
pregnancy to recruitment. Baseline glyce-
mia measures were not predictive of SGA
infants. During treatment, risk of SGA in-
fants was lower in women in the highest
tertile of capillary fasting glucose, but
there was no relationship with postpran-
dial glucose. The frequency of LGA in-
fants was associated with Polynesian
ethnicity, previous delivery of a baby
weighing4,000g,maternalweightgain
from early pregnancy to recruitment, and
A1C at recruitment. The rate of LGA in-
fants was increased in women whose cap-
illary glucose during treatment was in the
highest tertile. Other factors (not shown)
that did not relate to SGA or LGA infants
included chronic hypertension, gestation
at recruitment, smoking in pregnancy,
tertiary education, previous history of re-
current miscarriages/terminations, GDM
orhypertensivecomplications,andafam-
ily history of preeclampsia. The Breslow-
Day test and logistic regression analysis
showed no interactions of glycemic con-
trol with randomized treatment or with
maternal BMI in predicting the primary
Table 1—Baseline and treatment glycemia tertiles
Tertile 1
upper limit Tertile 1
Tertile 2
limits Tertile 2
Tertile 3
lower limit Tertile 3
Baseline measures
OGTT fasting glucose (mmol/l) 5.2 4.7  0.3 5.2–5.8 5.5  0.2 5.8 6.8  1.1
OGTT 2-h glucose (mmol/l) 8.8 7.5  1.0 8.8–9.9 9.4  0.3 9.9 11.6  1.8
A1C (%) 5.4 5.1  0.3 5.4–5.8 5.7  0.1 5.8 6.5  0.6
Treatment measures
Fasting capillary glucose (mmol/l) 4.9 4.6  0.3 4.9–5.3 5.1  0.1 5.3 5.9  0.6
Postprandial capillary glucose (mmol/l) 5.9 5.6  0.2 5.9–6.4 6.2  0.2 6.4 7.2  0.7
Mean capillary glucose (mmol/l) 5.4 5.2  0.2 5.4–5.8 5.7  0.1 5.8 6.5  0.6
Data are tertile boundaries and mean  SD glycemia measures within each tertile. Glucose and A1C were recorded to 1 decimal place.
Table 2—Outcomes by fasting, postprandial tertiles, and overall mean glucose tertiles
Fasting tertiles Postprandial tertiles Mean glucose tertiles
123 P* 123 P* 123 P*
Primary outcome components 22.9 32.5 39.6 0.001 25.6 29.4 40.3 0.001 23.0 31.1 41.4 0.001
Recurrent glucose 2.6 mmol/l 10.4 18.3 21.3 0.002 13.0 17.7 19.3 0.07 11.7 15.3 23.2 0.001
Respiratory distress 2.9 2.9 5.4 0.15 2.5 1.6 7.1 0.01 2.5 3.2 5.5 0.09
Phototherapy 5.4 8.1 10.8 0.03 7.1 6.9 10.5 0.18 5.4 9.7 9.3 0.13
Birth trauma 4.2 4.1 5.0 0.66 3.8 3.2 6.3 0.18 5.0 2.4 5.9 0.64
Apgar score 7 at 5 min 0.4 0 0.8 0.48 0 0 1.3 0.03 0 0 1.3 0.03
Prematurity: 37 weeks gestation 5.8 10.2 13.3 0.006 5.5 9.3 14.7 0.001 5.9 10.5 13.1 0.008
Maternal preeclampsia 4.2 4.9 9.6 0.01 3.4 4.4 10.9 0.001 3.4 5.2 10.1 0.002
Birth weight† 0.001‡ 0.001‡ 0.001‡
10th (customized) 13.8 11.4 6.7 0.01 11.8 10.5 9.7 0.46 13.8 9.7 8.4 0.06
90th (customized) 12.1 11.4 24.6 0.001 10.1 12.9 24.8 0.001 10.5 13.3 24.1 0.001
2,500 g 5.0 6.5 5.0 1.0 2.9 6.5 7.1 0.045 4.6 6.5 5.5 0.672
4,000 g 8.3 10.2 19.6 0.001 6.7 13.3 17.7 0.001 6.7 12.9 18.1 0.001
Data are frequency of outcome (%). *Cochrane-Armitage trend test. †Customized charts in general obstetric population with ethnicities similar to those of the MiG
population reported rates of SGA infants of 12.1–12.8% and of LGA infants of 8.4–8.8% (http://www.adhb.govt.nz/nwhealthinfo). ‡
2 test of three levels of
customized birth weight.
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LGA/SGA infants.
The ﬁrst multivariable analysis model
included baseline glycemia measures to
examine whether they related to the cho-
sen outcome measures (model 1). After
backward elimination, none of the base-
line glycemia measures predicted the pri-
mary outcome or preeclampsia, but
treatment capillary glucose was strongly
related. None of the glucose measures
predicted SGA infants. For LGA infants,
A1C at recruitment was the only predic-
tive glycemia measure (P  0.003). Com-
pared with the lowest A1C tertile, the
Table 4—Multiple logistic regression model 2: signiﬁcant factors relating to outcomes
Adjusted OR (95% CI) P
Primary outcome composite
Fasting capillary glucose on treatment
Tertile 1 1.00 0.001
Tertile 2 1.75 (1.17–2.63)
Tertile 3 2.66 (1.76–4.01)
Nulliparity
No 1.00 0.001
Yes 1.85 (1.30–2.65)
Previous baby 4,000 g
No 1.00 0.001
Yes 0.58 (0.37–0.90)
Preeclampsia
Postprandial capillary glucose on
treatment
Tertile 1 1.00 0.016
Tertile 2 1.38 (0.53–3.49)
Tertile 3 3.14 (1.31–7.32)
BMI category
Normal 1.00 0.036
Overweight 8.48 (1.09–66.22)
Obese 4.31 (0.55–33.50)
Weight gain (kg) from early
pregnancy to recruitment 1.06 (1.00–1.11) 0.034
Ethnicity category
European/Caucasian/mixed 1.00 0.041
Polynesian 2.40 (1.12–5.12)
Asian/other 0.86 (0.35–2.11)
Chronic hypertension
No 1.00 0.034
Yes 2.69 (1.08–6.73)
Previous gestational hypertension
No 1.00 0.008
Yes 3.26 (1.26–8.40)
Nulliparity 2.74 (1.32–5.70)
SGA or LGA SGA infants LGA infants
Postprandial capillary glucose on
treatment
Tertile 1 1.00 1.00 0.001
Tertile 2 0.89 (0.50–1.58) 1.30 (0.73–2.33)
Tertile 3 0.98 (0.54–1.78) 2.82 (1.65–4.84)
Previous baby 4,000 g
No 1.00 1.00 0.001
Yes 0.60 (0.28–1.28) 3.00 (1.84–4.89)
Nulliparity 1.20 (0.71–2.04) 0.84 (0.48–1.45)
Weight gain (kg) from early
pregnancy to recruitment 0.94 (0.90–0.99) 1.05 (1.02–1.09) 0.001
Maternal ﬁrst-degree relative: diabetes
No 1.00 1.00 0.01
Yes 2.04 (1.24–3.34) 0.84 (0.54–1.28)
Data are adjusted ORs (95% CI). BMI range was included in the model to determine whether there was any effect of BMI 30 kg/m
2. (Customized birth weights
already adjust for maternal BMI between 20 and 30 kg/m
2.)
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LGA infants of 2.64 (95% CI 1.33–5.24)
and the third tertile had an OR for LGA
infants of 4.0 (2.03–7.87).
The results of the second multivari-
able analysis model (excluding baseline
glycemia measures and thus including
larger numbers) are summarized in Table
4. Variables that were eliminated for all
outcomes are not shown. In this analysis,
fasting capillary glucose on treatment was
associated with the primary outcome
composite, and postprandial capillary
glucose was related to LGA infants and
preeclampsia. Overweight women were
more likely to develop preeclampsia than
normal-weight women, but the rate of
preeclampsia in obese women was not in-
creased. Numbers of women taking aspi-
rin (n  45) were too small to determine
whether this was a confounding factor.
Polynesian ethnicity, chronic hyperten-
sion, and previous gestational hyperten-
sion remained factors for preeclampsia.
Havingapreviousbabyweighing4,000
g reduced the risk of neonatal complica-
tions but increased the risk of LGA in-
fants. Weight gain from early pregnancy
to recruitment increased the risk of pre-
eclampsia and LGA infants.
CONCLUSIONS — The key ﬁnding
from this study is that capillary glucose
values during treatment for GDM with
metformin and/or insulin related strongly
and independently to the primary out-
come composite of neonatal outcomes, to
maternal preeclampsia, and to frequency
of LGA infants. These data are novel in
that the outcomes examined seem to be
sensitive to different levels of glycemia:
rates of neonatal hypoglycemia increased
between the lowest and middle tertiles of
glycemia control, whereas risk of LGA in-
fants and maternal preeclampsia in-
creased between the middle and highest
tertiles. These differential effects may be
important to consider when one is deter-
mining treatment goals and which out-
comes to report in assessing treatment of
GDM.
ThediagnosticOGTTvalueswerenot
predictive of outcomes, but A1C at re-
cruitment was predictive of LGA infants.
Itmaybethatinterventioninthetrialwas
too late to modify this outcome. The fetal
ultrasound measurements at recruitment
and at 37 weeks of gestation have not yet
been analyzed to see whether growth ve-
locity was modiﬁed differentially accord-
ing to glycemic control, as others have
shown (3).
During treatment, fasting capillary
glucose predicted neonatal complica-
tions, whereas postprandial capillary glu-
cose was related to risks of preeclampsia
and LGA infants. It is therefore important
to focus on both fasting and postprandial
glucose control to optimize outcomes.
The relationship between postprandial
glucose levels and complications may be
relevant for obese women without GDM,
who have higher postprandial glucose
levels and increased rates of preeclampsia
and LGA infants compared with lean
women(12).Inaddition,theHyperglyce-
mia and Adverse Pregnancy Outcome
(HAPO) study demonstrated that mater-
nal glycemia, as measured by a 75-g
OGTT at 28 weeks of gestation, is an im-
portant risk factor for preeclampsia and
LGA infants at values below those used
currently to diagnose GDM (13). A fur-
therstudyhasshownthatﬂuctuatingglu-
cose levels have a stronger effect on
endothelial function (important in the
pathogenesis of preeclampsia [14]) than
sustained hyperglycemia (15). From
these observations, it can be speculated
that reducing postprandial glucose ﬂuc-
tuations in obese women could reduce
rates of preeclampsia and/or LGA infants.
There was no independent effect of
obesity on the primary outcome compos-
ite, preeclampsia or LGA infants, consis-
tent with previous ﬁndings in women
treated with insulin (7). It may be that
pharmacotherapy more strongly modiﬁes
fetal nutrient supply than dietary inter-
vention alone, overriding the effects of
obesity per se.
There was no increase in SGA infants
in the lowest glucose tertile, but mean
glucose values were above the threshold
previously shown to increase risk of SGA
infants (9). Customized centiles were
used because, particularly in heteroge-
neous populations, they perform better
than does a population centile for identi-
fying SGA infants, both in the general ob-
stetric population and in women with
type 2 diabetes (11,16). It is recognized
that these calculators require further de-
velopment in relation to the adjustment
for ethnicity and maternal BMI (16).
The rate of SGA infants was increased
in women with a ﬁrst-degree relative with
diabetes. The reason for this may relate to
genetic associations between low birth
weight and type 2 diabetes (17).
There were no differences seen be-
tween metformin and insulin treatment
groups at different levels of glucose con-
trol. This ﬁnding suggests that, if met-
formin is used, supplemental insulin
should be used readily if glucose targets
are not achieved.
These data do not provide deﬁnitive
answers regarding optimal glucose tar-
gets. However, women with mean post-
treatment fasting capillary glucose 4.9
mmol/l had signiﬁcantly better outcomes
than women with posttreatment fasting
capillary glucose between 4.9 and 5.3
mmol/l. At 2 h postprandial, mean capil-
lary glucose 6.4 mmol/l was associated
with improved outcomes, and a further,
but small, improvement was seen with
meanpostprandialcapillaryglucose5.9
mmol/l. In an earlier study, women in a
“well-controlled” group had a mean fast-
ing capillary glucose of 4.7 mmol/l and
either a mean 1-h capillary glucose of 6.5
mmol/l or a mean 2-h capillary glucose
of 5.7 mmol/l, whereas a “less well-
controlled”grouphadameanfastingcap-
illary glucose of 5.3 mmol/l and either a
mean 1-h capillary glucose of 7.2 mmol/l
or a mean 2-h capillary glucose of 6.8
mmol/l (6). The glucose means in the
well-controlled group were very similar
to the means seen in women in the lowest
tertile in the current study. These data sug-
gest that clinicians should aim for lower tar-
gets than currently recommended.
In summary, these data demonstrate
that glucose control in women with GDM
is strongly related to pregnancy out-
comes. Targets for fasting and postpran-
dial capillary glucose may need to be lower
than current guidelines recommend.
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